GSR & Charlie Lee Back $100M MEI Pharma Private Placement – Pioneering Litecoin Treasury Strategy Hits Nasdaq

Crypto meets biotech in a nine-figure power play.

GSR just orchestrated a $100 million private placement into Nasdaq-listed MEI Pharma—with Litecoin creator Charlie Lee riding shotgun. The kicker? This marks the first institutional-grade Litecoin treasury strategy ever deployed.

Wall Street meets crypto’s silver medalist

While hedge funds still debate Bitcoin ETFs, GSR’s move injects Litecoin directly into corporate finance. The play: leverage MEI Pharma’s Nasdaq footing to legitimize LTC as a treasury asset. Because nothing says ‘mainstream adoption’ like a biopharma balance sheet.

Charlie Lee’s quiet coup

The Litecoin founder’s involvement signals strategic heft—though cynics might note it’s his first major play since selling his LTC stack at the 2017 peak. Timing is everything, especially when repositioning a ‘dinosaur’ altcoin for institutional appetites.

GSR’s endgame? Prove crypto treasuries aren’t just for Bitcoin maximalists and meme-coin degenerates. Though if this fails, there’s always the classic pharma pivot—reverse stock splits and drug trial hype.